MOTS-c · Research brief

How Many Doses Vial MOTS-c? — Real Peptides

Real Peptides Research TeamEditorial

Updated April 9, 202610 min read

51 WORDS

Short answer

A 5mg MOTS-c vial stored incorrectly isn't just less potent. It's potentially useless, and the dose count you calculated at reconstitution becomes meaningless the moment the peptide denatures. Here's what every researcher handling mitochondrial peptides needs to understand before drawing the first injection. We've supported hundreds of labs running MOTS-c protocols.

Key takeaways

A 5mg MOTS-c vial yields 10–20 doses depending on your target dose per injection. At 500mcg per dose you extract 10 doses, at 250mcg you extract 20 doses from the same vial.
Reconstitution volume determines concentration (mg/ml), not dose count. Two researchers can reconstitute identical vials to different concentrations and still extract the same number of doses by adjusting injection volume.
Standard research protocols dose MOTS-c subcutaneously at 250mcg to 5mg per injection, administered 2–3 times weekly, with most published studies using 5–15mg total per week across multiple doses.
MOTS-c must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days to prevent peptide degradation that renders dose counts meaningless.
Pharmaceutical-grade vials often include 5–10% overfill. A vial labelled 5mg may contain 5.2–5.5mg actual peptide mass, which affects dose accuracy in extended protocols if not accounted for in calculations.

We've supported hundreds of labs running MOTS-c protocols. The most common error isn't contamination or injection technique. It's dose calculation at the reconstitution stage, which determines whether your 5mg vial delivers 10 usable doses or 25.

How many doses are in a vial of MOTS-c?

A standard 5mg MOTS-c vial yields 10–20 doses when reconstituted with bacteriostatic water, depending on your target dose per injection. If you're dosing at 5mg per injection (a common research protocol), one vial = one dose. If you're working with 500mcg (0.5mg) per injection, that same vial delivers 10 doses. At 250mcg per injection, you extract 20 doses from a single 5mg vial. Provided your reconstitution math is accurate and your storage protocol prevents degradation.

Understanding MOTS-c Vial Concentrations and Peptide Mass

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondrial-derived peptide composed of 16 amino acids with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. It's typically supplied as lyophilised powder in vials ranging from 2mg to 10mg, with 5mg being the most common research-grade format. The lyophilised state is not the active form. It's a stable storage form that requires reconstitution with bacteriostatic water before use.

When you receive a vial labelled "5mg MOTS-c," that refers to the total peptide mass in the vial. Not the concentration. Concentration is created during reconstitution. If you add 1ml of bacteriostatic water to a 5mg vial, you've created a 5mg/ml solution. If you add 2ml, the concentration becomes 2.5mg/ml. This distinction matters because your dose count depends entirely on how much solution you inject per dose, not just the starting peptide mass.

Most research protocols dose MOTS-c subcutaneously at 250mcg to 5mg per injection, administered 2–3 times per week. The AMPK pathway activation and insulin sensitivity effects documented in published studies typically use doses in the 5–15mg/week range across multiple injections. At Real Peptides, every Mots C Peptide vial undergoes third-party purity testing to confirm the stated peptide mass. The dose count you calculate is only as accurate as the peptide mass you start with.

Reconstitution volume is the variable researchers control. A 5mg vial reconstituted with 2ml bacteriostatic water creates a 2.5mg/ml solution. Meaning every 0.1ml (10 units on a standard insulin syringe) contains 250mcg of MOTS-c. If your protocol calls for 500mcg per dose, you'd draw 0.2ml (20 units), and that 5mg vial yields exactly 10 doses. If you reconstitute the same 5mg vial with 5ml bacteriostatic water instead, you create a 1mg/ml solution. Now every 0.5ml contains 500mcg, and your vial still yields 10 doses, but each injection volume is larger.

Calculating Exact Dose Counts from Reconstituted MOTS-c Vials

Dose count calculation follows a three-step sequence: determine total peptide mass, choose reconstitution volume, identify target dose per injection. The formula is straightforward: (Total Peptide Mass ÷ Target Dose Per Injection) = Number of Doses. A 5mg vial dosed at 500mcg per injection yields 10 doses. The same vial dosed at 250mcg yields 20 doses. At 1mg per dose, you extract 5 doses.

The error happens when researchers confuse concentration with dose count. Concentration (mg/ml) tells you how much peptide is in each millilitre of solution. It does not directly tell you how many doses you have. Two labs can reconstitute identical 5mg vials to different concentrations (one at 2mg/ml, one at 5mg/ml) and still extract the same number of doses if they adjust injection volume accordingly.

Here's the practical workflow: You have a 5mg MOTS-c vial. Your protocol specifies 500mcg per injection. You want a concentration that makes measurement easy on a standard 1ml insulin syringe marked in 0.01ml increments. Reconstitute with 2ml bacteriostatic water to create a 2.5mg/ml solution. Now, 0.2ml (20 units on the syringe) = 500mcg. Your vial yields 10 doses of 0.2ml each. If you wanted smaller injection volumes, reconstitute with 1ml instead. Creating a 5mg/ml solution where 0.1ml (10 units) = 500mcg. Same dose count, different volumes.

Common reconstitution volumes and resulting concentrations for a 5mg vial: 1ml water = 5mg/ml, 2ml water = 2.5mg/ml, 2.5ml water = 2mg/ml, 5ml water = 1mg/ml. Most researchers prefer 2ml or 2.5ml because it creates concentrations that align cleanly with syringe graduations. A 2.5mg/ml solution means every 0.1ml contains 250mcg, making math simple during dose preparation.

Vial overfill is a variable some researchers forget. Pharmaceutical-grade lyophilised peptides often include 5–10% overfill to account for handling loss and ensure the stated dose is deliverable. A vial labelled 5mg may contain 5.2–5.5mg actual peptide mass. High-purity suppliers like Real Peptides disclose overfill percentages in certificates of analysis. If your vial contains 5.3mg and you calculated doses assuming 5.0mg, you're underdosing slightly on every injection. For single-dose studies, this matters less. For 12-week titration protocols, cumulative underdosing compounds.

Comparison Table: MOTS-c Dose Yields by Reconstitution Protocol

The table below shows how vial size, reconstitution volume, and target dose per injection combine to determine total dose count. Each scenario assumes standard subcutaneous research dosing with no peptide loss during handling.

Vial Size (mg)	Reconstitution Volume (ml)	Concentration (mg/ml)	Target Dose Per Injection (mcg)	Injection Volume (ml)	Total Doses from Vial	Professional Assessment
5mg	2ml	2.5mg/ml	500mcg	0.2ml	10 doses	Standard protocol. Clean syringe graduations, minimal handling error
5mg	2.5ml	2mg/ml	250mcg	0.125ml	20 doses	Best for low-dose multi-week studies. Maximises vial economy
5mg	1ml	5mg/ml	5mg	1ml	1 dose	Single high-dose administration. Common in acute metabolic studies
10mg	4ml	2.5mg/ml	500mcg	0.2ml	20 doses	Preferred for extended protocols. Reduces reconstitution frequency
2mg	2ml	1mg/ml	250mcg	0.25ml	8 doses	Small vial format. Useful when peptide stability post-reconstitution is a concern
5mg	5ml	1mg/ml	1mg	1ml	5 doses	Larger injection volumes. May be less practical for subcutaneous administration

What If: MOTS-c Dosing Scenarios

What If I Miscalculated My Reconstitution Volume and Created the Wrong Concentration?

You can't remove bacteriostatic water once added. The solution is permanently diluted to the concentration you created. If you added too much water (creating a lower concentration than intended), adjust your injection volume upward to deliver the correct peptide mass per dose. For example, if you intended 2.5mg/ml but accidentally created 1mg/ml, double your injection volume to maintain the same dose. If you added too little water and the concentration is too high, you can draw smaller volumes. But very high concentrations (above 5mg/ml) may increase injection site discomfort and peptide aggregation risk.

The cleanest solution is to start fresh with a new vial if the error is significant. Attempting to "fix" a badly miscalculated reconstitution by adding more water after the initial mix risks uneven peptide distribution, especially if the vial has already been stored for days. For labs running multi-week studies where dosing consistency is critical, the cost of a replacement vial is negligible compared to compromised data integrity.

What If My Reconstituted MOTS-c Vial Appears Cloudy or Contains Visible Particles?

Discard it immediately. Cloudiness or particulate matter indicates peptide aggregation, contamination, or improper reconstitution. MOTS-c reconstituted correctly with bacteriostatic water should appear as a clear, colourless solution. Cloudiness suggests the peptide has denatured or that the bacteriostatic water was contaminated prior to mixing. Visible particles can also result from injecting air forcefully into the vial during reconstitution, which causes foaming and protein destabilisation.

Never attempt to filter or centrifuge a cloudy peptide solution to "salvage" it. Once aggregation occurs, the peptide's tertiary structure is compromised, meaning it will not bind to cellular receptors as intended. The amino acid sequence may still be intact, but the bioactive conformation is lost. This is why reconstitution technique matters: add bacteriostatic water slowly down the side of the vial, never directly onto the lyophilised powder, and allow the peptide to dissolve passively without shaking or vigorous agitation.

What If I Need to Store a Reconstituted Vial for Longer Than 28 Days?

Peptide degradation accelerates in aqueous solution even under refrigeration. The 28-day guideline reflects the maximum stability window during which MOTS-c retains at least 95% of its initial potency when stored at 2–8°C. Beyond 28 days, hydrolysis and oxidation of methionine and tryptophan residues reduce receptor binding affinity. Some labs extend storage to 45–60 days under tightly controlled conditions (refrigeration with minimal freeze-thaw cycles and sterile handling), but this introduces potency uncertainty that compromises reproducibility.

If your study protocol requires dosing beyond 28 days, reconstitute smaller vials more frequently rather than storing one large vial long-term. A 2mg vial reconstituted fresh every three weeks will outperform a 10mg vial stored for two months. Alternatively, aliquot the reconstituted peptide into sterile vials immediately after mixing and freeze aliquots at −20°C. Single-use aliquots thawed once eliminate repeated freeze-thaw cycles that fragment peptide chains. Freeze-thaw stability data for MOTS-c shows significant potency loss after three freeze-thaw cycles, so aliquoting is a one-time process, not a repeated convenience.

What If I'm Dosing MOTS-c Daily Instead of 2–3 Times Per Week?

Daily dosing increases your dose count proportionally but does not change the total peptide mass in the vial. If your protocol specifies 250mcg daily and you reconstitute a 5mg vial to yield 20 doses at 250mcg each, that vial lasts 20 days on a daily schedule versus approximately 7–10 weeks on a 2–3 times per week schedule. The concentration and injection volume remain the same. Only the consumption rate changes.

Daily dosing at lower per-injection amounts is common in metabolic studies examining chronic AMPK activation and mitochondrial biogenesis, where steady-state peptide levels may produce different outcomes than pulsed dosing. The trade-off is vial turnover: daily protocols consume peptide faster, requiring more frequent reconstitution and increasing contamination risk from repeated vial access. If you're drawing from the same vial 20 times over 20 days, sterile technique becomes the limiting factor. Each needle puncture introduces potential contamination even with alcohol swabs and proper handling.

The Blunt Truth About MOTS-c Dose Calculations

Here's the honest answer: most dose calculation errors don't happen because the math is hard. They happen because researchers assume the vial label tells them everything they need to know. It doesn't. A vial labelled "5mg" is peptide mass, not dose count. Dose count is a function of how much you inject per administration, and that's entirely researcher-determined. There is no "standard" number of doses in a MOTS-c vial. The same 5mg vial yields 1 dose, 10 doses, or 20 doses depending on your protocol.

The second mistake is trusting that lyophilised powder lasts indefinitely. It doesn't. MOTS-c stored as lyophilised powder at −20°C remains stable for 12–24 months, but once you add water, the degradation clock starts immediately. Refrigeration at 2–8°C slows hydrolysis and oxidation but does not stop it. By day 28 post-reconstitution, potency begins declining measurably. By day 60, you're dosing degraded peptide fragments, not intact MOTS-c, and your receptor activation data becomes unreliable.

If you're running a protocol where dosing accuracy matters. Metabolic studies, mitochondrial function assays, insulin sensitivity trials. Calculate your dose count before reconstitution, choose a vial size that matches your study duration, and discard any solution older than 28 days regardless of how much peptide remains. The cost of replacing a partially used vial is negligible compared to publishing results based on degraded compound concentrations you didn't measure.

For researchers seeking research-grade MOTS-c with verified purity and accurate peptide mass, Real Peptides provides third-party certificates of analysis with every vial, confirming the stated dose is deliverable without guesswork. Accurate dose counts start with accurate starting material. And that requires synthesis precision most suppliers don't document.

Dose calculation is straightforward when you treat peptide mass, reconstitution volume, and target dose as three separate variables instead of assuming the vial label does the math for you. It doesn't. You do.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

A 5mg MOTS-c vial yields 10–20 doses depending on your target dose per injection. If you dose at 500mcg per injection, the vial provides 10 doses. At 250mcg per injection, you extract 20 doses from the same vial. The total peptide mass is fixed at 5mg — dose count varies based on how much you administer per injection, which is determined by your research protocol.

Choose a reconstitution volume that creates a concentration aligned with your target dose and syringe graduations. For a 5mg vial dosed at 500mcg per injection, adding 2ml bacteriostatic water creates a 2.5mg/ml solution where 0.2ml (20 units on a standard insulin syringe) equals 500mcg. The formula is: desired concentration (mg/ml) = total peptide mass (mg) ÷ reconstitution volume (ml). Most researchers use 2–2.5ml for 5mg vials because it produces concentrations that simplify dose measurement.

Peptide stability declines significantly beyond 28 days post-reconstitution even under refrigeration at 2–8°C. Hydrolysis and oxidation of methionine and tryptophan residues reduce MOTS-c potency, compromising dose accuracy and receptor binding affinity. Some labs extend storage to 45–60 days, but this introduces reproducibility risks. For protocols requiring longer timelines, reconstitute smaller vials more frequently or aliquot the solution into sterile single-use vials and freeze at −20°C immediately after mixing — avoiding repeated freeze-thaw cycles.

You create a lower concentration than intended, but the total peptide mass remains unchanged — meaning you can still extract the same number of doses by increasing your injection volume. If you accidentally created a 1mg/ml solution when you intended 2.5mg/ml, draw 2.5 times the volume per dose to deliver the correct peptide amount. The downside is larger injection volumes, which may be less practical for subcutaneous administration and increase injection site discomfort.

MOTS-c is dosed at 250mcg to 5mg per injection 2–3 times weekly, targeting AMPK pathway activation and insulin sensitivity improvements. SS-31 (elamipretide), by contrast, is typically dosed at significantly lower amounts — 0.25mg to 1mg per injection — because it acts directly on mitochondrial membranes rather than through metabolic signaling pathways. The dose count per vial differs accordingly: a 5mg vial of MOTS-c at 500mcg per dose yields 10 doses, while a 5mg vial of SS-31 at 250mcg per dose yields 20 doses. The peptides target different mechanisms and are not interchangeable.

Cloudiness indicates peptide aggregation, contamination, or denaturation — discard the vial immediately and do not attempt to use it. Properly reconstituted MOTS-c appears as a clear, colourless solution. Cloudiness occurs when bacteriostatic water is added too forcefully (causing foaming and protein destabilisation), when the water itself is contaminated, or when the peptide has been exposed to temperatures above 8°C during storage. Always add water slowly down the side of the vial and allow passive dissolution without shaking.

Lyophilised MOTS-c stored at −20°C remains stable for 12–24 months, significantly longer than the 28-day stability window of reconstituted peptide solution. The lyophilised state removes water, preventing hydrolysis and oxidation reactions that degrade peptide bonds. Once you add bacteriostatic water, the degradation clock starts immediately — refrigeration at 2–8°C slows but does not stop potency loss, which is why reconstituted peptides should be used within 28 days for maximum reliability.

Yes, provided you maintain sterile technique with every draw — but contamination risk increases with each vial access. Use a fresh sterile needle for every draw, swab the vial stopper with 70% isopropyl alcohol before each puncture, and never inject air into the vial while drawing solution (this creates positive pressure that can pull contaminants back through the needle). For studies involving 10+ subjects or extended timelines, consider aliquoting the reconstituted peptide into individual sterile vials immediately after mixing to eliminate repeated access to a single vial.

Visual inspection cannot detect peptide degradation reliably — degraded MOTS-c often appears identical to fresh solution. The only definitive method is mass spectrometry or HPLC analysis, which few research labs perform routinely. Practical indicators include storage duration beyond 28 days, temperature excursions above 8°C, cloudiness or particulate formation, and off-label odour (though bacteriostatic water itself has a faint benzyl alcohol smell). If dosing consistency matters to your study outcomes, adhere strictly to the 28-day post-reconstitution timeline and discard remaining solution regardless of appearance.

Published preclinical studies examining MOTS-c’s effects on insulin sensitivity, AMPK activation, and mitochondrial biogenesis typically use doses ranging from 5mg to 15mg per week, administered as 2–3 subcutaneous injections. A common protocol is 5mg per injection three times weekly (15mg total per week). The specific dose depends on study endpoints, subject weight, and administration route — intraperitoneal injection in rodent models uses higher per-kilogram doses than subcutaneous protocols, and dosing extrapolation to human-equivalent amounts requires allometric scaling adjustments.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA